Dr. Anne Marijn Kramer, MD, PhD, is a postdoctoral research fellow in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Kramer received her medical degree (with honors) from Amsterdam University in 2013. She conducted her PhD studies at University College London, studying binding kinetics of Chimeric Antigen Receptor (CAR) T cells. Her research at Stanford University focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.

Honors & Awards

  • ASH abstract achievement award, American Society of Hematology (12/09/2023)
  • EHA Junior Research Grant, European Hematology Association (09/01/2022)
  • Paul Fentener van Vlissingen Fellowship, Lymph&Co (09/01/2022)
  • Prins Bernhard Cultuurfondsbeurs, Prins Bernhard Cultuurfonds (06/01/2013)
  • VSBfonds beurs, VSBfonds (06/01/2013)
  • NIHR GOSH/UCL ICH BRC PhD Scholarship, NIHR Great Ormond Street Hospital/UCL Institute of Child Health Biomedical Research Centre (04/01/2014)
  • CCA grant co-applicant, Cancer Center Amsterdam (03/01/2020)

Boards, Advisory Committees, Professional Organizations

  • President, Dutch Junior Society of Internal Medicine (2020 - 2021)
  • Board Member, Dutch Society of Internal Medicine (2020 - 2021)

Professional Education

  • Doctor of Medicine, University of Amsterdam (2013)
  • Doctorandus, University of Amsterdam (2011)
  • Diploma, Stedelijk Gymnasium Johan van Oldenbarnevelt (2005)
  • Doctor of Philosophy, University College London (2017)
  • PhD, University College London, Cancer Immunotherapy (2017)
  • MD, University of Amsterdam, Medicine (2013)

Stanford Advisors


  • Kramer AM, Kokalaki E, Pule MA. "United KingdomOff-rate CAR", UCLB, Sep 1, 2016
  • Mekkaoui L, Kramer AM, Ghorashian S, Pule MA. "United KingdomA CAR against CD19 based on a novel binder", UCLB, Mar 1, 2015

All Publications

  • CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, S., Bharadwaj, S., Johnston, L. J., Liedtke, M., Lowsky, R., Meyer, E., Negrin, R., Rezvani, A., Shizuru, J., Sidana, S., Egeler, E., Mavroukakis, S., Tunuguntla, R., Gkitsas-Long, N., Retherford, A., Brown, A. K., Gramstrap-Petersen, A. L., IbaƱez, R. M., Feldman, S. A., Miklos, D. B., Mackall, C. L., Davis, K. L., Frank, M., Ramakrishna, S., Muffly, L. 2024


    Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22+ malignancies with progression after CD19-directed therapies. Using on-site, automated, closed-loop manufacturing, we conducted parallel Phase 1b clinical trials investigating a humanized CD22-CAR with 41BB costimulatory domain in children and adults with heavily treated, relapsed/refractory (r/r) B-ALL. Of 19 patients enrolled, 18 had successful CD22-CAR manufacturing, and 16 patients were infused. High grade (3-4) cytokine release syndrome (CRS) and immune effector-cell-associated neurotoxicity syndrome (ICANS) each occurred in only one patient; however, three patients experienced immune-effector-cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Twelve of 16 patients (75%) achieved CR with an overall 56% MRD-negative CR rate. Duration of response was overall limited (median 77 days), and CD22 expression was downregulated in 4/12 (33%) available samples at relapse. In summary, we demonstrate that closed-loop manufacturing of CD22-CAR T cells is feasible and is associated with a favorable safety profile and high CR rates in pediatric and adult r/r B-ALL, a cohort with limited CD22-CAR reporting.

    View details for DOI 10.1038/s41375-024-02220-y

    View details for PubMedID 38491306

    View details for PubMedCentralID 4993814

  • Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL Kramer, A., Hamilton, M. P., Prabhu, S., Desai, M., Kuo, A., Ehlinger, Z., Agarwal, N., Su, Y., Gkitsas, N., Fowler, C., Keerthi, V., Retherford, A., Klysz, D., Tunuguntla, R., Feldman, S., Sahaf, B., Baird, J. H., Muffly, L. S., Mackall, C. L., Miklos, D. B., Good, Z., Frank, M. J. AMER SOC HEMATOLOGY. 2023
  • Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible Su, Y., Kramer, A., Hamilton, M. P., Agarwal, N., Feldman, S., Sahaf, B., Kuo, A., Mackall, C. L., Muffly, L. S., Miklos, D. B., Frank, M. J. AMER SOC HEMATOLOGY. 2023
  • CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y., Kramer, A., Reschke, A., Jeyakumar, N., Bharadwaj, S., Schultz, L., Ramakrishna, S., Davis, K. L., Sahaf, B., Feldman, S., Mackall, C. L., Miklos, D. B., Muffly, L. S., Frank, M. J. AMER SOC HEMATOLOGY. 2023